Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 2.45
OREX's Cash to Debt is ranked higher than
75% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. OREX: 2.45 )
OREX' s 10-Year Cash to Debt Range
Min: 2.21   Max: No Debt
Current: 2.45

Equity to Asset 0.11
OREX's Equity to Asset is ranked lower than
53% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. OREX: 0.11 )
OREX' s 10-Year Equity to Asset Range
Min: -0.73   Max: 0.78
Current: 0.11

-0.73
0.78
F-Score: 5
Z-Score: 0.12
M-Score: 10.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -54.99
OREX's Operating margin (%) is ranked higher than
53% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. OREX: -54.99 )
OREX' s 10-Year Operating margin (%) Range
Min: -107754.55   Max: -54.99
Current: -54.99

-107754.55
-54.99
Net-margin (%) -67.59
OREX's Net-margin (%) is ranked higher than
52% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.01 vs. OREX: -67.59 )
OREX' s 10-Year Net-margin (%) Range
Min: -105954.55   Max: -67.59
Current: -67.59

-105954.55
-67.59
ROE (%) -183.07
OREX's ROE (%) is ranked lower than
53% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. OREX: -183.07 )
OREX' s 10-Year ROE (%) Range
Min: -235.61   Max: -42.04
Current: -183.07

-235.61
-42.04
ROA (%) -22.16
OREX's ROA (%) is ranked higher than
55% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. OREX: -22.16 )
OREX' s 10-Year ROA (%) Range
Min: -879.2   Max: -19.09
Current: -22.16

-879.2
-19.09
ROC (Joel Greenblatt) (%) -935.36
OREX's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. OREX: -935.36 )
OREX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -193375   Max: -3874.08
Current: -935.36

-193375
-3874.08
Revenue Growth (3Y)(%) 73.50
OREX's Revenue Growth (3Y)(%) is ranked higher than
99% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. OREX: 73.50 )
OREX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 73.5
Current: 73.5

0
73.5
EBITDA Growth (3Y)(%) -23.00
OREX's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. OREX: -23.00 )
OREX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 7.6
Current: -23

0
7.6
EPS Growth (3Y)(%) -18.00
OREX's EPS Growth (3Y)(%) is ranked higher than
62% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. OREX: -18.00 )
OREX' s 10-Year EPS Growth (3Y)(%) Range
Min: -55.4   Max: 153.4
Current: -18

-55.4
153.4
» OREX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

OREX Guru Trades in Q1 2014

RS Investment Management 2,223,585 sh (+15.19%)
Paul Tudor Jones Sold Out
Steven Cohen 676,800 sh (-83.07%)
» More
Q2 2014

OREX Guru Trades in Q2 2014

RS Investment Management 2,179,142 sh (-2.00%)
» More
Q3 2014

OREX Guru Trades in Q3 2014

RS Investment Management 2,229,642 sh (+2.32%)
» More
Q4 2014

OREX Guru Trades in Q4 2014

RS Investment Management Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OREX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 43.40
OREX's P/B is ranked lower than
58% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. OREX: 43.40 )
OREX' s 10-Year P/B Range
Min: 0.85   Max: 43.4
Current: 43.4

0.85
43.4
P/S 16.68
OREX's P/S is ranked lower than
55% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.38 vs. OREX: 16.68 )
OREX' s 10-Year P/S Range
Min: 11.67   Max: 1495
Current: 16.68

11.67
1495
PFCF 41.10
OREX's PFCF is ranked higher than
85% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1165.60 vs. OREX: 41.10 )
OREX' s 10-Year PFCF Range
Min: 27.63   Max: 41.1
Current: 41.1

27.63
41.1
POCF 39.68
OREX's POCF is ranked higher than
76% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.96 vs. OREX: 39.68 )
OREX' s 10-Year POCF Range
Min: 5.91   Max: 79.5
Current: 39.68

5.91
79.5
EV-to-EBIT -26.57
OREX's EV-to-EBIT is ranked lower than
51% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.80 vs. OREX: -26.57 )
OREX' s 10-Year EV-to-EBIT Range
Min: -25.2   Max: 2.5
Current: -26.57

-25.2
2.5
Current Ratio 7.11
OREX's Current Ratio is ranked higher than
90% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. OREX: 7.11 )
OREX' s 10-Year Current Ratio Range
Min: 3.3   Max: 19.3
Current: 7.11

3.3
19.3
Quick Ratio 7.07
OREX's Quick Ratio is ranked higher than
91% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. OREX: 7.07 )
OREX' s 10-Year Quick Ratio Range
Min: 3.3   Max: 19.3
Current: 7.07

3.3
19.3
Days Sales Outstanding 16.90
OREX's Days Sales Outstanding is ranked higher than
96% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. OREX: 16.90 )
OREX' s 10-Year Days Sales Outstanding Range
Min: 8.2   Max: 16.9
Current: 16.9

8.2
16.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 65.30
OREX's Price/Net Cash is ranked higher than
82% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. OREX: 65.30 )
OREX' s 10-Year Price/Net Cash Range
Min: 1.01   Max: 50.5
Current: 65.3

1.01
50.5
Price/Net Current Asset Value 55.90
OREX's Price/Net Current Asset Value is ranked higher than
70% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. OREX: 55.90 )
OREX' s 10-Year Price/Net Current Asset Value Range
Min: 1   Max: 35.65
Current: 55.9

1
35.65
Price/Tangible Book 43.50
OREX's Price/Tangible Book is ranked lower than
55% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. OREX: 43.50 )
OREX' s 10-Year Price/Tangible Book Range
Min: 0.99   Max: 34.21
Current: 43.5

0.99
34.21
Price/Median PS Value 0.10
OREX's Price/Median PS Value is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. OREX: 0.10 )
OREX' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 8.33
Current: 0.1

0.08
8.33
Earnings Yield (Greenblatt) -3.70
OREX's Earnings Yield (Greenblatt) is ranked higher than
55% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. OREX: -3.70 )
OREX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -3.8   Max: 3901
Current: -3.7

-3.8
3901

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:JXS.Germany,
Orexigen Therapeutics Inc was incorporated in Delaware in September 2002. Company is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates are NB32, which has completed Phase III clinical trials and which is currently being studied in a cardiovascular outcomes trial, and Empatic, which has completed Phase II clinical trials. Both NB32 and Empatic regulate appetite and energy expenditure through central nervous system activity. NB32 is a fixed dose combination of bupropion and naltrexone. Company develops its product candidates for large markets traditionally served by primary care physicians. In order to effectively promote NB32 to these physicians, in September 2010, it entered into a collaboration agreement with Takeda to develop and commercialize NB32 in the United States, Canada and Mexico. It maintains an aggressive intellectual property strategy, which includes patent and trademark filings in multiple jurisdictions including the United States and other commercially significant markets. It relies on a combination of in-licensed patent rights, its own patent rights, trademarks, trade secrets and know-how to protect NB32 and Empatic. Its products used in clinical trials have been produced by outside contractors under its supervision. Company competes with AstraZeneca, Athersys, Inc., Bristol-Myers Squibb, Norgine BV, Novo Nordisk A/S, among others.
» More Articles for OREX

Headlines

Articles On GuruFocus.com
Oxford Industries (OXM) Solid Growth Metrics, Orexigen Therapeutics (OREX) European Anti-Obesity App Mar 27 2015 
Orexigen Therapeutics' Bright Future Mar 03 2015 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 16 2012 
Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
Steve Cohen Bets On Orexigen Ahead of FDA Approval Feb 01 2011 
Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2010 


More From Other Websites
Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer Mar 30 2015
8:46 am Orexigen Therapeutics announces that Tom Cannell has joined as Chief Commercial Officer Mar 30 2015
Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer Mar 30 2015
Leerink: Europe Deal Coming For Orexigen Therapeutics Mar 30 2015
OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds... Mar 27 2015
Barrack, Rodos & Bacine Has Filed an Investor Class Action Against Orexigen Therapeutics, Inc. Mar 27 2015
Orexigen's Obesity Drug Mysimba Gains European Approval - Analyst Blog Mar 27 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in... Mar 27 2015
Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Orexigen Therapeutics, Inc. Mar 27 2015
US pre-open: Futures point to another day in the red ahead of Yellen's speech Mar 27 2015
Ahead of the Bell: Orexigen shares rise Mar 27 2015
Ahead of the Bell: Orexigen shares rise Mar 27 2015
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events Mar 26 2015
Orexigen gets approval to market weight loss drug in Europe Mar 26 2015
Orexigen gets approval to market weight loss drug in Europe Mar 26 2015
Orexigen's Mysimba™ Approved in Europe for the Treatment of Obesity Mar 26 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of OREXIGEN THERAPEUTICS, INC. of... Mar 25 2015
OREX Shareholder Alert: Investigation on Behalf of Orexigen Therapeutics, Inc. Investors Announced... Mar 25 2015
Deadline in Lawsuit for Investors in Orexigen Therapeutics, Inc. (NASDAQ:OREX) Shares Announced by... Mar 24 2015
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Mar 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK